The first ADC for HER2+ BC, trastuzumab emtansine (T-DM1, or Kadcyla®), was FDA approved in 2013 for HER2+ mBC patients who previously received trastuzumab and taxane [58] (Table 1). The gene discussed is ERBB2; the disease is breast cancer.